Preview

Журнал инфектологии

Расширенный поиск

Вакцины на основе мРНК для профилактики коронавирусной инфекции

https://doi.org/10.22625/2072-6732-2022-14-1-5-19

Аннотация

С марта 2020 г. Всемирная организация здравоохранения объявила пандемию коронавирусной инфекции. Практически сразу начались разработки вакцин, согласно рекомендациям, опубликованным Всемирной организацией здравоохранения. В настоящий момент 137 вакцин в мире проходят клинические испытания и 194 находятся на стадии доклинических исследований. Кандидатные вакцины разработаны с использованием различных технологических платформ. В данной статье представлены данные по безопасности и эффективности мРНК-вакцин против новой коронавирусной инфекции у детей и подростков. Отмечен высокий популяционный эффект данных вакцин до распространения вариантов дельта и омикрон и некоторое снижение эффективности в отношении новых вариантов коронавируса. Также описаны результаты применения данных препаратов у пациентов из группы риска: онкологические больные и лица с аутоиммунными и аутовоспалительными заболеваниями.

В обзоре проанализированы данные литературы о безопасности и эффективности применения мРНКвакцин против коронавирусной инфекции. Используемые в настоящее время мРНК вакцины против новой коронавирусной инфекции безопасны и эффективны даже среди пациентов из групп риска (онкологические больные и лица с аутоиммунными или аутовоспалительными заболеваниями).

Результаты исследований и пострегистрационного контроля за мРНК-вакцинами подчеркивают их профиль безопасности и эффективности, что подтверждает возможность и необходимость в массовом использовании. 

Об авторах

С. М. Харит
Детский научно-клинический центр инфекционных болезней; Санкт-Петербургский государственный педиатрический медицинский университет
Россия

Харит Сусанна Михайловна – руководитель отдела профилактики инфекционных заболеваний; профессор кафедры инфекционных заболеваний у детей ФП и ДПО, д.м.н., профессор

Санкт-Петербург



И. В. Фридман
Детский научно-клинический центр инфекционных болезней
Россия

Фридман Ирина Владимировна – старший научный сотрудник отдела профилактики инфекционных заболеваний, к.м.н. 

Санкт-Петербург



Список литературы

1. Методические рекомендации по выявлению, расследованию и профилактике побочных проявлений после иммунизации. Утв. МЗ РФ России от 12.04.2019.

2. CONSIDERATIONS FOR EVALUATION OF COVID19 VACCINES. Points to consider for manufacturers of COVID19 vaccines. Version 25 November 2020 https://www.who.int/publications/m/item/considerations-for-the-assessment-ofcovid-19-vaccines-for-listing-by-who

3. National Institute for Biological Standards and Control https://www.nibsc.org/products/brm_product_catalogue/detail_page.aspx?catid=20/136

4. WHO Working definitions of SARS-CoV-2 Variants of Interest and Variants of Concern https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update

5. T. R Fleming , P. R Krause , M. Nason , I. M Longini, A.M. M Henao-Restrepo/COVID-19 vaccine trials: The use of active controls and non-inferiority studies/ Clinical Trials 2021, Vol. 18(3) 335–342

6. European Centre for Disease Prevention and Control. Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA – Version 1.0. Stockholm: ECDC;2021. Stockholm, December 2021 PDF ISBN 978-92-9498-562-0 doi: 10.2900/099023 Catalogue number TQ-06-21-216-EN-N

7. N. Pardi, M. J. Hogan, Frederick W. Porter, D.Weissman /mRNA vaccines – a new era in vaccinology/ Nature reviews. drug discovery, volume 17, April 2018, 261-279 Published online 12 Jan 2018.

8. E. Dolgin. Тhe tangled history of MRN vaccines Nature | Vol 597 | 16 September 2021 https://media.nature.com/original/magazine-assets/d41586-021-02483-w/d41586-021-02483-w.pdf

9. S. E. Oliver, J.W. Gargano, M. Marin, et al/ The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020, Morbidity and Mortality Weekly Report , Early Release / Vol. 69 December 13, 2020.

10. Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine EUA amendment review memorandum. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/media/148542/download

11. CDC. COVID data tracker. Atlanta, GA: US Department of Health and Human Services, CDC; 2021.https://covid.cdc.gov/covid-data-tracker/#demographicsovertime.

12. Dawood FS, Porucznik CA, Veguilla V, et al. Incidence rates, household infection risk, and clinical characteristics of SARS-CoV-2 infection among children and adults in Utah and New York City, New York. JAMA Pediatr 2021. PMID:34623377

13. Lam-Hine T, McCurdy SA, Santora L, et al. Outbreak associated with SARS-CoV-2 B.1.617.2 (Delta) variant in an elementary school–Marin County, California, May–June 2021. MMWR Morb Mortal Wkly Rep 2021;70:1214–9. PMID:34473683

14. K. R. Woodworth, D. Moulia, J. P. Collins et al The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years – United States, November 2021, MMWR / November 12, 2021 / Vol. 70 / No. 45 1579 -1583

15. WHO. Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: background document to the WHO interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing, 14 January 2021. Geneva: World Health Organization; 2021.

16. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing,https://www.medbox.org/document/interim-recommendations-for-use-of-the-pfizerbiontech-covid-19-vaccinebnt162b2-under-emergency-use-listing#GO).

17. Public Health England COVID-19 vaccine surveillance report Week 20.- https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/990089/Vaccine_surveillance_report_-_week_20.pdf

18. Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine. 2021;385:1761-73. doi:10.1056/NEJMoa2110345.

19. Parry, H.; Bruton, R.; Stephens, C.; Brown, K.; Amirthalingam, G.; Hallis, B.; et al. Extended interval BNT162b2 vaccination enhances peak antibody generation in older people.:medRxiv;https://www.medrxiv.org/content/10.1101/2021.05.15.21257017v1.

20. K.R. Woodworth, J.W. Gargano, H. M. Scobie et al The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years – United States, May 2021 M. Wallace, MMWR / May 21, 2021 / Vol. 70 / No. 20/ 749-752

21. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine – United States, December 2020 ,S.E. Oliver, J. W. Gargano, M .Marin, et al, MMWR / January 1, 2021 / Vol. 69 / No. 51-52 1653-1656 https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm695152e1-H.pdf

22. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID19WHOreferencenumber:WHO/2019-CoV/vaccines/SAGE_recommendation/mRNA-1273/2021.

23. Spikevax1 (COVID-19 mRNA vaccine. An overview of Spikevax and why it is authorized in the EU.https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf

24. S. Mbaeyi, S.E. Oliver, J. P. Collins, M. Godfrey et al The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines – United States, 2021 MMWR / November 5, 2021 / Vol. 70 / No. 44 1545-1552

25. Spikevax (COVID-19 mRNA vaccine [nucleoside modified].An overview of Spikevax and why it is authorised in the EU https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-eparproduct-information_en.pdf

26. P. B. Gilbert, D. C. Montefiori, A. McDermott и др.Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial, med.Rxiv preprint doi: 10.1101/2021.08.09.21261290.

27. European Centre for Disease Prevention and Control. Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA – Version 1.0. Stockholm: ECDC; 2021. Stockholm,December doi:10.2900/099023

28. COVID-19 Vaccine Breakthrough Infections Reported to CDC – United States, January 1–April 30, 2021 , MMWR / May 28, 2021 / Vol. 70 / No. 21

29. W. H. Self, M. W. Tenforde, J.P. Rhoads. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions – United States, March–August 2021, MMWR / September 24, 2021 / Vol. 70 / No. 38 1337-1343.

30. L. A. McNamara, R. E. Wiegand, R.M Burk. Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data/Lancet 2022; 399: 152–60 Published Onlin //doi.org/10.1016/S0140-6736(21)02226-1

31. Z. Vokó, Z. Kiss, G Surján, I. Wittmann, C. Müller, M. Kásler et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary – The HUN-VE study , Clinical Microbiology and Infection Available online 25 November 2021 In Press, Journal Pre-proof Open AccessPublished: November 24, 2021.

32. P. Nordstrom. Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members //P. Nordstrom, M. Ballin, A. Nordstrom, JAMA Intern Med. 2021; 181(12):1589-1595. doi:10.1001/jamainternmed.2021.5814 Published online October 11, 2021

33. International Vaccine Access Center, Health JHBSoP, and, Organization WH. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review Updated November4

34. Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R et al. COVID-19 Vaccine Effectiveness by Product and Timing in New York State.

35. Arjun Puranik, Patrick J. Lenehan, Eli Silvert1 , Michiel J.M. Niesen , J. Corchado-Garcia1 , John C. O’Horo , Abinash Virk , Melanie D. Swift , John Halamka , Andrew D. Badley , A.J. Venkatakrishnan1 , Venky Soundararajan. Comparison of two highly-effective mRNA vaccines for COVID19 during periods of Alpha and Delta variant prevalence //doi.org/10.1101/2021.08.06.21261707

36. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ et al. Waning Immunity after the BNT162b2 Vaccine in Israel. New England Journal of Medicine. 2021.

37. Y. P. Tabak, X. Sun, ; T. A. Brennan, S.K. Chaguturu Incidence and Estimated Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Among Persons Tested in US Retail Locations, May 1 to August 7, 2021 , JAMA Network Open. 2021;4(12):e2143346. doi:10.1001/jamanetworkopen.2021.

38. Y. Liu J. Liu, H. Xia, et al., Neutralizing Activity of BNT162b2-Elicited Serum N Engl J Med 384;15 nejm.org April 15, 2021.

39. H. Scobie. Update on Omicron Variant. ACIP Meeting December 16, 2021 https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-12-16/06-COVID-Scobie-508.pdf

40. А.Wilhelm M. Widera, K. Grikscheit et al Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267432;

41. S. Cele, L. Jackson , K. Khan, SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection medRxiv preprint doi: https://doi.org/10.1101/2021.12.08.21267417;

42. W. Dejnirattisai, R. H Shaw, P.Supasa и др. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by postimmunisation serum https://www.medrxiv.org/content/10.1101/2021.12.10.21267534v1;

43. Zahradník J, Tuekprakhon A, Ginn HM, et al. Receptor binding and escape from Beta antibody responses drive Omicron-B.1.1.529 evolution. 2021; bioRxiv preprint //doi.org/10.1101/2021.12.03.471045

44. S. A. Buchan, H. Chung, K. A. Brown и др. Effectiveness of COVID-19 vaccines against Omicron or Delta infection medRxiv preprint doi: //doi.org/10.1101/2021.12.30.21268565

45. А.Rössler L. Riepler D. Bante et al. SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent medRxiv preprint //doi.org/10.1101/2021.12.08.21267491

46. S. Cele, L. Jackson , K. Khan, SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection medRxiv preprint doi: https://doi.org/10.1101/2021.12.08.21267417;

47. D. Cromer, A. Reynaldi , T.E. Schlub, A. K. Wheatley , J.r A. Juno , K. Subbarao, S. J. Kent, J. A. Triccasd, M. P. Davenport. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Nature Medicine / VOL 27 / July 2021.

48. S. Y Tartof, J. M Slezak, H. Fischer, V. Hong, et al.Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study Lancet 2021; 398: 1407–16 Published Online October 4, 2021 https://doi.org/10.1016/S0140-6736(21)02183-8

49. M. W. Tenforde, W. H. Self, E. A. Naioti, и др. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults – United States, March–July 2021 / MMWR / August 27, 2021 / Vol. 70

50. P. Havers, H. Pham, C. A. Taylor, M.Whitaker, K.Patel. et al. COVID-19-associated hospitalizations among vaccinated and unvaccinated adults ≥18 years – COVID-NET, 13 states January 1-July 24, 2021 medRxiv preprint doi: https://doi.org/10.1101/2021.08.27.21262356

51. N. Barda, N. Dagan, C.Cohen, M. A Hernán et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study Lancet 2021; 398: 2093–100 Published Online October 29, 2021 https://doi.org/10.1016/S0140-6736(21)02249-2

52. E S. Rosenberg, D. R. Holtgrave, V. Dorabawila, M. Conroy et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status – New York, May 3–July 25, 2021 MMWR / September 17, 2021 / Vol. 70 / No. 37

53. L. Monin, A. G Laing, M.Mu oz-Ruiz, D. R McKenzie, I. del Molino del Barrio Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study / Lancet Oncol 2021 Published Online April 27, 2021.

54. B. J. Boyarsky, W. A. Werbel, R.K. Avery, A.A. R. Tobian, A. B. Massie, D. L. Segev, J. M. Garonzik-Wang, Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsB/ JAMA Published online May 5, 2021 https://jamanetwork.com/on 05/12/2021

55. Benotmane, G. Gautier, P. Perrin, J. Olagne, N. Cognard, S. Fafi-Kremer, S. Caillard. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses JAMA September 21, 2021 Volume 326, Number 11 , р.1063-1064 doi:10.1001/jama.2021.12339

56. N. Kamar, F. Abravanel, O.r Marion, C. Couat, J. Izopet, A.Del Bello, Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients N Engl J Med 385;7 nejm.org August 12, 2021.

57. A. Le Bourgeois, M. Coste-Burel, T. Guillaume, P. Peterlin, A. Garnier, M.C. Béné, P. Chevallier, Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant JAMA Network Open.2021;4(9):e2126344.

58. M. Espi, X. Charmetant, T. Barba, C. Pelletier , L. Koppe, и др. Justification, safety, and efficacy of a third dose of mRNA vaccine in maintenance hemodialysis patients: a prospective observational study medRxiv preprint doi: https://doi.org/10.1101/2021.07.02.21259913

59. S. Bhandari Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis Kidney International (2021) 100, 702; https://doi.org/10.1016/j.kint.2021.07.003

60. B. J Boyarsky, J. A Ruddy, C. M Connoll и др Antibody response to a single dose of SARSCoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases Ann Rheum Dis August 2021 Vol 80 No 8, р1098-1099.

61. S.Y. Wong , R. Dixon , V. M Pazos , S. Gnjatic, J.-F.Colombel , K. Cadwell Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies Gastroenterology. 2021 Aug;161(2):715-718.e4.

62. K. Dooling. Evidence to Recommendation Framework: An Additional Dose of mRNA COVID-19 Vaccine Following a Primary Series in Immunocompromised People https://www.cdc.gov/vaccines/acip/meetings/downloads/slides2021-08-13/02-COVID-Dooling-508.pdf

63. S.E. Oliver, M. Wallace, I. See, S. Mbaeyi et al. Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices – United States, December 2021 MMWR / January 21, 2022 / Vol. 71 / No. 3.

64. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14–23, 2020, MMWR / January 15, 2021 / Vol. 70 / No. 2: 46-51

65. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine – United States, December 21, 2020–January 10, 2021 MMWR / July 9, 2021 / Vol. 70 / No. 27, 977-982.

66. COVID-19 Vaccine Safety Technical (VaST) Work Group G. M. Lee (ACIP Chair),R. H. Hopkins, (NVAC Chair) Advisory Committee on Immunization Practices , August 30, 2021.

67. Israeli Ministry of Health. Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021 [Press release]. Jerusalem, Israel: Israeli Ministry of Health; 2021. https://www. gov.il/en/departments/news/01062021-03,

68. Shay DK, Shimabukuro TT, De Stefano F. Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol 2021. Epub June 29, 2021.

69. J. W. Gargano, M. Wallace, S. C. Hadler, G. Langley et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021 MMWR / July 9, 2021 / Vol. 70 / No. 27, 978-982;

70. ACIP.Presentation,November2021https://www.cdc.gov/vaccines/acip/meetings/downloads/slides2021-11-2-3/04-COVID-Oster-508.pdf

71. Summary of product characteristics https://www.ema.europa.eu/en/documents/product-information/spikevaxpreviously-covid-19-vaccine-moderna-epar-product-information_en.pdf

72. S. Xu, R. Huang, L. S. Sy, S. C. Glenn и др. COVID-19 Vaccination and Non–COVID-19 Mortality Risk – Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021 MMWR / October 29, 2021 / Vol. 70 / No. 43

73. H. Xia, J. Zou, C. Kurhade, H. Ca и др. Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine bioRxiv preprint doi: https://doi.org/10.1101/2022.01.21.476344

74. P. Sah, T. N Vilches, S. M. Moghadas, M. C. Fitzpatrick, E. C Schneider A.P. Galvani Impact of accelerating booster vaccination amidst Omicron surge in the United States medRxiv preprint doi: https://doi.org/10.1101/2022.01.22.22269655

75. Press release Joint Committee on Vaccination and Immunisation (JCVI) advice on COVID-19 booster vaccines for those aged 18 to 39 and a second dose for ages 12 to 15 https://www.gov.uk/government/news/jcvi-advice-on-covid19-booster-vaccines-for-those-aged-18-to-39-and-a-seconddose-for-ages-12-to-15

76. COVID-19 booster vaccine programme for winter 2021 to 2022: JCVI statement, November 2021 https://www.gov.uk/government/publications/covid-19-booster-vaccineprogramme-for-winter-2021-to-2022-jcvi-statement-november-2021 Update to JCVI advice on booster vaccination in adults, 15 November 2021 https://www.gov.uk/government/publications/covid-19-booster-vaccine-programme-for-winter2021-to-2022-jcvi-statement-november-2021/update-to-jcviadvice-on-booster-vaccination-in-adults-15-november-2021

77. TECHNICAL REPORT Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA 11 November 2021 https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-strategies-and-deployment-plans-Nov-2021.pdf

78. L. Burnett,K.J.L. Jackson,D.B. Langley et al., Immunizations with diverse sarbecovirus receptorbinding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability2021, Immunity 54, 2908–2921 https://doi.org/10.1016/j.immuni.2021.10.019

79. This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series. https://www.who.int/news-room/feature-stories/detail/theeffects-of-virus-variants-on-covid-19-vaccines

80. Preliminary data indicate COVID-19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron variant News 11/01/2022 https://www.ema.europa.eu/en/news/preliminary-data-indicate-covid-19-vaccines-remain-effective-against-severe-disease-hospitalisation


Рецензия

Для цитирования:


Харит С.М., Фридман И.В. Вакцины на основе мРНК для профилактики коронавирусной инфекции. Журнал инфектологии. 2022;14(1):5-19. https://doi.org/10.22625/2072-6732-2022-14-1-5-19

For citation:


Kharit S.M., Fridman I.V. mRNA-based vaccines for the prevention of coronavirus infection. Journal Infectology. 2022;14(1):5-19. (In Russ.) https://doi.org/10.22625/2072-6732-2022-14-1-5-19

Просмотров: 377


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2072-6732 (Print)